Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;37(1):222-225.
doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8.

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli  1 , Gerhard Zugmaier  2 , Carmelo Rizzari  3 , Joan D Morris  4 , Bernd Gruhn  5 , Thomas Klingebiel  6 , Rosanna Parasole  7 , Christin Linderkamp  8 , Christian Flotho  9 , Arnaud Petit  10 , Concetta Micalizzi  11 , Yi Zeng  4 , Rajendra Desai  12 , William N Kormany  4 , Cornelia Eckert  13 , Anja Möricke  14 , Mary Sartor  15 , Ondrej Hrusak  16 , Christina Peters  17 , Vaskar Saha  18   19 , Luciana Vinti  20 , Arend von Stackelberg  21
Affiliations

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli et al. Leukemia. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FL reports advisory board membership for Amgen, Novartis, Bellicum Pharmaceuticals, Neovii, Vertex, and is on the Speakers’ Bureau for Amgen, Novartis, Miltenyi, Medac, Jazz Pharmaceuticals, and Takeda, outside the submitted work. GZ, JDM, YZ, and WNK are employed by Amgen. GZ has patents 20190300609 and 20130323247 licensed. CR reports personal fees from Amgen, Jazz Pharmaceuticals, Sobi, and grants and personal fees from Shire and Medac, outside the submitted work. RD supports Amgen as an employee of IQVIA. AM reports grants from Amgen during the conduct of the study and personal fees from Shire, outside the submitted work. CP reports membership on board of directors or advisory committee for Amgen, and travel support from Amgen, Neovii, Jazz, and Novartis, and Speakers’ Bureau for Riemser, Amgen, Novartis, and Medac. VS reports personal fees from Amgen during the conduct of the study. AvS reports personal fees from Amgen, Shire, Jazz, Roche, and MorphoSys, outside the submitted work. RP reports advisory board membership for Amgen, Novartis, and Shire and is on the Speakers’ Bureau for Jazz, Servier, and Amgen. BG, TK, CL, CF, AP, CM, CE, MS, OH, and LV have no disclosures.

Figures

Fig. 1
Fig. 1. Survival by treatment arm and event-free survival subgroup analysis.
A Survival probability over time is shown by treatment arm, i.e., blinatumomab or chemotherapy, for both event-free survival (left panel) and overall survival (right panel). Censoring indicated by circles and triangles for blinatumomab and chemotherapy, respectively. CI confidence interval, HR hazard ratio. B Event-free survival hazard ratios with 95% confidence intervals are shown for subgroups as indicated. *Stratification by marrow status (M1) at randomization and MRD after induction therapy. HR for M2 was not evaluable (n = 4 in each arm). BM bone marrow, CI confidence interval, EM extramedullary, EFS event-free survival, HR hazard ratio, MRD minimal residual disease.
See this image and copyright information in PMC

References

    1. Eckert C, Parker C, Moorman AV, Irving JAE, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175–89. doi: 10.1016/j.ejca.2021.03.034. - DOI - PubMed
    1. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16. doi: 10.1182/blood-2012-02-265884. - DOI - PubMed
    1. Salzer WL, Burke MJ, Devidas M, Dai Y, Heerema NA, Carroll AJ, et al. Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131. Abstract from the 2021 American Society of Clinical Oncology Annual Meeting. J Clin Oncol. 2021;39:10004. doi: 10.1200/JCO.2021.39.15_suppl.10004. - DOI
    1. Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833–42. doi: 10.1001/jama.2021.0669. - DOI - PMC - PubMed
    1. Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel PG, et al. Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020;10:77. doi: 10.1038/s41408-020-00342-x. - DOI - PMC - PubMed

Publication types

MeSH terms